Evidence

BROWSE BY STUDY TYPE OR CONFERENCE
All
  • All
  • MODEL VALIDATION
  • CLINICAL VALIDATION
  • AACR
  • ASCO
  • ASH
BROWSE BY YEAR
All
  • All
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • Archive
Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients

ESMO,

Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers

ESMO,

Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy

ESMO Gastrointestinal Oncology,

Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)

Blood Journal,

The impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM): a Cellworks computational biosimulation pilot study

Neuro-Oncology,

Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A

WCLC,

Predictions of overall survival (OS) and progression-free survival (PFS) for specific therapeutic interventions in newly diagnosed glioblastoma multiforme (GBM) using Cellworks Singula: myCare-024-04

ASCO Meeting Library,

Cellworks Singula therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: myCare-004

ASCO Meeting Library,

STAY INFORMED

Top